"It’s important for us to think about ITP as any other autoimmune disorder. When it’s flaring, fatigue is associated." -- Michelle Sholzberg, MDCM, MSc, St. Michael’s Hospital, Toronto The study, ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Sanofi (SNYNF) announced an update on their ongoing clinical study.

Several areas of discordance were observed, including contributing causes for delay in diagnosis, with patients perceiving extended wait times as a significant contributing factor. Patients were ...

Immune thrombocytopenia (ITP) doesn’t have a cure and can be unpredictable. There are two main types of ITP, acute and chronic. The acute type usually lasts six months or less. It’s more common in ...

STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease ...